<DOC>
	<DOCNO>NCT01336582</DOCNO>
	<brief_summary>Primary Objective : Evaluation pharmacokinetic equivalence two Docetaxel formulation term AUC Cmax .</brief_summary>
	<brief_title>Pharmacokinetic Study SYP-0704A Taxotere Treat Patient With Advanced Solid Cancer</brief_title>
	<detailed_description>Comparison pharmacokinetic parameter ( T1/2β , CL , Vdss ) Safety measure adverse event</detailed_description>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Subjects age 18 year old . Subjects whose write informed consent obtain comply local regulatory requirement prior participation trial . Subjects histologically cytologically confirm advanced solid tumor . Subjects suitable candidate single agent docetaxel therapy advance solid tumor fail standard therapy . Subjects fully recover reversible toxic effect prior therapy . The prior chemotherapy , immunotherapy , hormone therapy , surgery , and/or radiotherapy complete least 21 day first administration investigational product . Subjects major surgery tumor ablation within 2 week prior screening/baseline visit . Subjects history metastasis currently metastasis central nervous system ( CNS ) . Subjects preexist sensory motor neuropathy grade ≥ 2 base NCI CTCAE V3.0 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>suitable candidate</keyword>
	<keyword>single agent docetaxel therapy</keyword>
	<keyword>Advanced Solid Tumor</keyword>
</DOC>